Biomedical engineering
RNA-based immunotherapies have gained significant attention in recent years due to their potential in reprogramming the immune system to combat cancer. A recent study published in Nature Biomedical Engineering has made groundbreaking discoveries that have led to the development of a new class of RNA therapeutics called Universal Immune Fortifying
Biomedical engineering
RNA-based immunotherapies have gained significant attention in recent years due to their potential in reprogramming the immune system to combat cancer. A recent study published in Nature Biomedical Engineering has made groundbreaking discoveries that have led to the development of a new class of RNA therapeutics called Universal Immune Fortifying
Cancer
As Tammie Thrower lay in palliative care, her primary concern was finding a place to live. Despite battling stage four bowel cancer since 2023, she was evicted from her home in January, thrusting her into homelessness. Her story, though shocking, is common in Brisbane, where 21 people died of diagnosed
Cancer
A groundbreaking DNA-based blood test, Galleri, has been revealed to have a remarkable accuracy rate of detecting over 50 types of cancer before symptoms appear. Developed by Grail, a US-based biotech company, and currently being evaluated by the UK's National Health Service (NHS), this test has the potential
Cancer
A pioneering Galleri blood test has shown remarkable promise in detecting over 50 types of cancer in their early stages, with a significant portion of cases identified before symptoms even appear. The test, designed to pinpoint the organ or tissue of origin in cancer cases, has achieved an impressive accuracy
Cancer
Research on multi-cancer detection (MCED) blood tests has significant implications for the implementation of these screenings in the future. The studies highlight the crucial role that patient expectations play in emotional, cognitive, and social responses to potential cancer diagnoses. A recent study from Queen Mary University of London has shed
Cancer
A study published in the Irish Journal of Medical Science has investigated the systemic and biologic agent choices of dermatologists in Ireland for patients with psoriasis and a cancer diagnosis. The research found that methotrexate was the most commonly selected agent for all scenarios, including a 5-year remission, while fumaric
Cancer
Scientists at University College London have engineered a rare type of immune cell, ðþð³T cells, to survive longer and grow faster, and when supercharged with a B7-H3 antibody, they can use two methods of attack to kill cancer cells. This breakthrough could lead to new treatments for people with
Cancer
A new tumor-informed circulating-tumor DNA (ctDNA) blood test, HPH MRD, has been made available in Germany by MVZ HPH Institute for Pathology and Hematopathology GmbH. Developed in collaboration with Haystack Oncology, a subsidiary of Quest Diagnostics, the test utilizes Haystack MRD technology to detect ultralow levels of ctDNA with exceptional
Cancer
A groundbreaking study on the Galleri test, a universal blood test for cancer, has yielded impressive results, showing a 62% accuracy in identifying individuals with cancer. The test, which is being trialled in the NHS, can detect over 50 types of cancer, often before symptoms appear. The Pathfinder 2 study,
Cancer
Researchers at Genomics England, in partnership with NHS England, are conducting a revolutionary study that screens 100,000 newborn babies for dozens of genetic conditions. The Generation Study, launched in 2024, uses whole genome sequencing to detect over 200 rare conditions, some of which can cause a progressive loss of
Cancer
Patients with relapsed or refractory natural killer/T-cell lymphoma (R/R NKTL) have limited treatment options, but a new combination therapy of epigenetic therapy with an anti-PD-1 antibody shows promising results. The study, published in Cancer Discovery, a journal of the American Association for Cancer Research (AACR), suggests that the
